Nov. 24 at 4:57 PM
$FATN What excites me about Mainz Biomed is the roadmap in the US, eAArly DETECT 2 aiming for roughly 2,000 average risk patients, then a 15,000 patient pivotal ReconAAsense supported by Quest Diagnostics, and all that future optionality is still being valued at around
$5M while the modeled fair value is
$14 with +1,328.57% upside